Sotorasib for KRAS G12C-Mutated Lung Cancer

preview_player
Показать описание
Sarah B. Goldberg, MD, MPH interview on Sotorasib for KRAS G12C-Mutated Lung Cancer

--

Follow PracticeUpdate:

  1. PracticeUpdate
  2. cancer
  3. oncology
  4. subject: lung cancer
  5. physician
  6. doctor
Рекомендации по теме
Sotorasib: first targeted 0:00:57

Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

Sotorasib for KRAS 0:06:22

Sotorasib for KRAS G12C Mutated Advanced Non-Small Cell Lung Cancer

ASCO 2021 Lung 0:05:26

ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation

Sotorasib for KRAS 0:06:33

Sotorasib for KRAS G12C-Mutated Lung Cancer

Treating KRAS G12C 0:01:42

Treating KRAS G12C Mutations

Sotorasib shows as 0:04:19

Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC

Current treatment strategies 0:01:10

Current treatment strategies KRASG12C–mutated NSCLC

CodeBreaK 200: sotorasib 0:02:42

CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC

Sotorasib outperforms docetaxel 0:02:59

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson

Sotorasib vs. Adagrasib 0:04:13

Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC - Case Based Panel Discussion

#ESMO22 Highlights on 0:02:35

#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study

Sotorasib continues to 0:03:58

Sotorasib continues to show potential in KRAS-mutant NSCLC | Ferdinandos Skoulidis

CodeBreak 100: sotorasib 0:06:28

CodeBreak 100: sotorasib in KRAS-mutated NSCLC

Safety of sotorasib 0:07:19

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

ESMO highlights: KRAS 0:02:09

ESMO highlights: KRAS G12C inhibitors

Sotorasib for advanced 0:01:58

Sotorasib for advanced non-small cell lung cancer

Real-world outcomes by 0:05:14

Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC

KRYSTAL-1 and CodeBreak 0:01:26

KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer

Targeting non-G12C KRAS 0:01:10

Targeting non-G12C KRAS mutations in NSCLC

CodeBreaK 100: Patient-reported 0:02:32

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

Treatment strategies for 0:01:37

Treatment strategies for KRAS-mutant NSCLC with co-mutations

Phase II CodeBreak 0:03:01

Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC

Highlights on sotorasib 0:04:09

Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study

Recurrent irAEs observed 0:01:46

Recurrent irAEs observed with sequential sotorasib after chemoimmunotherapy for KRASG12C NSCLC